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Thresholds for red blood cell transfusion following cardiac surgery vary by hospital and
surgeon. The TITRe2 multi-centre randomised controlled trial aims to randomise 2000
patients from 17 United Kingdom centres, and tests the hypothesis that a restrictive trans-
fusion threshold will reduce postoperative morbidity and health service costs compared to
a liberal threshold. Patients consent to take part in the study pre-operatively but are only
randomised if their haemoglobin falls below 9 g/dL during their post-operative hospital
stay. The primary outcome is a binary composite outcome of any serious infectious or
ischaemic event in the ﬁrst three months after randomisation. Many challenges have been
encountered in the set-up and running of the study.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. IntroductionOver 6% of all red blood cell (RBC) usage in the United
Kingdom (UK) occurs in cardiac surgery [1]. RBC transfu-
sion is essential in some cardiac surgical patients for the
management of life-threatening haemorrhage. In most
cases, however, decisions to give a RBC transfusion are
made because the Hb concentration has fallen to a level
or threshold at which the physician is uncomfortable
[2,3]. The transfusion threshold varies across different
cardiac surgery units and between different surgeons,
which contributes to the wide variation in blood usage
observed in cardiac surgical units (25–95%) [4]. The thresh-
old variation stems from a lack of evidence regarding what
1 Trial registration: The trial was registered as ISRCTN70923932 before
starting to recruit.
452 R.C.M. Brierley et al. / Transfusion and Apheresis Science 50 (2014) 451–461constitutes a safe level of anaemia following cardiac
surgery.
Viral, bacterial or prion infection, and haemolytic trans-
fusion reactions are well publicised risks of RBC transfu-
sion, but these are rare [5]. Immunosuppression, lung
injury or organ dysfunction, on the other hand, may poten-
tially occur in every recipient [6]. The risk of pneumonia,
estimated to be approximately 13% following coronary
artery bypass graft (CABG) surgery, has been observed to
increase by 5% per unit of RBCs or platelets transfused
[7]. In addition, retrospective studies investigating associa-
tions between RBC transfusion and speciﬁc morbidity after
cardiac surgery have shown associations with nosocomial
pneumonia [8], sternal wound infection [9], and severe
sepsis [10]. A comparison of propensity matched pairs of
transfused versus non-transfused patients, using data from
over 3000 patients treated in 145 European ICUs, observed
that RBC transfusion conferred a relative risk of mortality
of 1.4 (95% conﬁdence interval 1.24–1.36) [11]. RBC trans-
fusion has also been reported to be associated with an in-
crease in mortality up to ﬁve years after cardiac surgery
[2,12].
In addition to the direct costs of blood products, RBC
transfusion may increase hospital costs by prolonging
ICU and hospital stay. In abdominal [13] and orthopaedic
surgery [14], avoiding RBC transfusion was associated with
a reduction in total treatment costs of approximately
£7000 per patient in 2012 prices. Findings of increased
mortality up to ﬁve years after surgery suggest that there
may be costs arising from long term transfusion-related
morbidity or delayed complications [2,12]. There are also
wider resource issues relating to the use of blood compo-
nents nationally. Donor blood is an increasingly scarce
resource, with up to 10% of donors excluded as a conse-
quence of variant Creutzfeldt–Jakob disease restrictions
on the donor pool [5]. Increasing scarcity and the costs
associated with attracting new donors, as well as the intro-
duction of additional measures aimed at increasing the
safety of donated blood, are very likely to increase the di-
rect costs of RBC transfusion.
There is little evidence about the optimal transfusion
threshold for cardiac surgery patients. Healthy human sub-
jects can tolerate Hb levels as low as 5 g/dL without ad-
verse consequences [15], and Hb levels as low as 7 g/dL
are safely tolerated in non-cardiac surgery, trauma, and
ICU patients [16]. The FOCUS trial hypothesised that el-
derly trauma patients undergoing hip surgery randomised
to a liberal (Hb level <10.0 g/dL) transfusion trigger would
recover faster than those randomised to a restrictive (Hb
level <8.0 g/dL) trigger [17]. The trial demonstrated no
superiority for the liberal transfusion trigger and the
authors concluded that a more restrictive threshold should
be used, because of the absence of harm and the clear eco-
nomic beneﬁt of using less blood. In contrast, the Canadian
Transfusion Requirements in Critical Care (TRICC) study
hypothesised that non-cardiac ICU patients randomised
to a restrictive (Hb level <7.0 g/dL) would do no worse than
those randomised to a liberal (Hb level <10.0 g/dL) transfu-
sion trigger [18]. The restrictive trigger resulted in a 54%
relative reduction in RBC transfusion and also a reduction
in the frequency of organ dysfunction and 30-day mortal-ity, effects which were attributed to a reduction in red cell
transfusion associated morbidity. A subsequent meta-anal-
ysis of TRICC and other studies conﬁrmed that reducing
RBC transfusion thresholds reduced postoperative transfu-
sion rates, further supporting the use of more restrictive
thresholds. Cardiac complications showed a non-signiﬁ-
cant reduction [19].
However, the applicability of these observations to a
cardiac surgery population is unclear because the level
of anaemia considered to be ‘safe’ is thought to be higher
in the presence of cardiac disease. A post hoc analysis of
the subgroup of patients with coronary artery disease in
the TRICC study found no difference in 30-day mortality
between the restrictive and liberal threshold groups
[20]. On the basis of the TRICC study results, some cardiac
units in the UK routinely use a transfusion trigger of 7 g/
dL without any apparent detriment to patients [21,22].
However, to date, there has been no high quality random-
ised trial of different post-operative RBC transfusion
thresholds in a UK population of cardiac surgery patients.
The most recent randomised controlled trial (RCT) of lib-
eral versus restrictive transfusion thresholds in cardiac
surgery patients randomised 502 patients in a hospital
in Brazil. No difference was found between the groups
(testing a hypothesis of non-inferiority) but the study ran-
domised all patients consented before surgery and was
underpowered for a clinically important non-inferiority
margin [23].
1.1. Aims and objectives
We have undertaken a multi-centre RCT of Transfusion
Indication Threshold Reduction (TITRe2) on transfusion
rates, morbidity and healthcare resource use following
cardiac surgery. The trial is designed to test the hypothesis
that a restrictive threshold for RBC transfusion (Hb 7.5 g/dL
and/or haematocrit (Hct) 22%) will reduce post-operative
morbidity and health service costs compared to a liberal
threshold (Hb 9 g/dL and/or Hct 27%).
Speciﬁc objectives of this multi-centre RCT are to:
A. Estimate the difference in the risk of a post-opera-
tive infection or ischaemic event between restrictive
and liberal transfusion thresholds.
B. Compare the effects of restrictive and liberal trans-
fusion thresholds with respect to a range of second-
ary outcomes.
C. Estimate the cost-effectiveness of a restrictive com-
pared to a liberal Hb transfusion threshold.
2. Patients and methods
2.1. Trial design
The study is a multi-centre RCT comparing two alterna-
tive transfusion thresholds, restrictive versus liberal
thresholds, for RBC transfusion in the UK National Health
Service (NHS).1
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Seventeen UK cardiac surgery centres are participating
in the study. Participant eligibility criteria are as inclusive
as possible to promote the applicability of the evidence ob-
tained during the trial; see Table 1 for inclusion and exclu-
sion criteria.
Potential trial participants receive a patient information
leaﬂet describing the study, either in the post or faxed to the
hospital where they are waiting for surgery, and are then
seen in hospital by a member of the research teamwho an-
swers any questions, conﬁrms eligibility and obtains writ-
ten informed consent before surgery. Details of reason(s)
for non-participation (e.g. reason for being ineligible or re-
fusal) are carefully documented wherever possible. For pa-
tients who consent, post-operative Hb and/or Hct levels
from blood samples analysed as part of the patient’s usual
care are monitored carefully; if the Hb level drops below
9.0 g/dL or Hct below 27% then the registered patient be-
comes eligible for randomisation. Randomisation should
take place as soon as possible after the Hb level has dropped
below 9.0 g/dL or Hct below 27%, and at the latest within
24 h. Patients are eligible for randomisation at any timedur-
ing their post-operative stay, irrespective of whether: (a) a
RBC transfusion has been given prior to randomisation; (b)
a prior breach of the 9.0 g/dL Hb/Hct of 27% threshold was
missed; or c) any element of the primary outcome has oc-
curred. See Fig. 1 for an illustration of the trial schema.
The duration of intervention in the trial is the duration of
the patient’s care under the consultant cardiac surgeon or a
maximum of three months after the date of randomisation,
whichever is shorter. Almost always, the duration of care
under the cardiac surgeon is the period of hospitalisation
after surgery. The duration of follow-up in the trial is until
three month follow-up assessment questionnaires have
been completed or until three months after randomisation
if a participant refuses to complete the questionnaires.
2.3. Interventions
The two groups are deﬁned as follows:
Liberal (control, similar to current practice): Transfuse if
post-operative Hb level falls below 9.0 g/dL or Hct falls
below 27%.Table 1
Inclusion/exclusion criteria.
Inclusion criteria:
 Adults of either sex, aged 16 years or over undergoing cardiac surgery (de
genital cardiac disease)
 Post-operative Hb level below 9.0 g/dL or Hct below 27 at any stage duri
 Written informed consent
Exclusion criteria:
 Patients undergoing emergency cardiac surgery (deﬁned as surgery takin
 Patients who are prevented from having blood and blood products accord
 Patients with congenital or acquired platelet, red cell or clotting disorder
 Patients with ongoing or recurrent sepsis
 Patients unable to give full informed consent for the study (e.g. learning
 Patients with critical limb ischaemia (deﬁned as rest pain in affected lim
 Patients already participating in another interventional research studyRestrictive (experimental): Transfuse if post-operative
Hb level falls below 7.5 g/dL or Hct falls below 22%.
Thresholds can be expressed either as Hb or Hct be-
cause anaemia is assessed by varying instruments across
centres and stages of care (intensive care and ward).
Where both Hb and Hct values are available, transfusion
is indicated if either of these values falls below the allo-
cated threshold (7.5 g/dL or Hct of 22% versus 9.0 g/dL or
Hct of 27%). Hereafter, only Hb levels are referred to but
this should be interpreted as Hb or Hct.
The objective is to maintain the Hb level at or above
9.0 g/dL in the liberal group and at or above 7.5 g/dL in
the restrictive group. For both groups Hb levels are moni-
tored and transfusions given accordingly for the duration
of the patient’s post-operative hospital stay on the cardiac
ICU or cardiac surgical ward. If the Hb drops below
(‘‘breaches’’) the allocated threshold a RBC transfusion
should be given as soon as possible, at least within 24
hours. One unit of RBC should be transfused at a time
and the Hb level checked before transfusing another unit.
Clinicians are allowed to transfuse, or refuse to transfuse,
in contravention of the allocated threshold but the rea-
son(s) why must be documented on the study case report
form (CRF). Other aspects of post-operative care are pro-
vided in accordance with usual care.
2.4. Outcomes
2.4.1. Primary outcome
The primary outcome is a binary composite outcome of
any serious infectious (sepsis or wound infection) or
ischaemic event (stroke, MI, gut infarction or AKI) in the
ﬁrst three months after randomisation. Qualifying events
and the manner in which they are veriﬁed are detailed in
Table 2.
Events occurring post-discharge only contribute to the
primary outcome if the potentially qualifying event results
in admission to hospital or death, except for post-discharge
wound infections; these are ascertained using a modiﬁed
ASEPSIS post-discharge wound assessment (see Table 2)
[24,25]. Documentary evidence about events suspected to
qualify for the primary outcome is sent to the co-ordinat-
ing centre and veriﬁed by research nurses who are blinded
to allocation. Suspected post-randomisation MIs areﬁned as CABG, valvular or aortic surgery or surgical correction of con-
ng the patient’s post-operative hospital stay
g place before the end of the same working day as admission)
ing to a system of beliefs (e.g. Jehovah’s Witnesses)
s (patients with iron deﬁcient anaemia are not excluded)
or language difﬁculties)
b associated with peripheral vascular disease)
Patient discharged from hospital
Postal or telephone follow-up & QoL 
assessment 3-months post-randomisation
Liberal (Control) Group:
Eligible for transfusion when 
Hb < 9.0g/dL / Hct < 27
(n = 1000)
Restrictive (Experimental) Group
Continue monitoring Hb / Hct level.
Eligible for transfusion if 
Hb < 7.5g/dL / Hct < 22
(n = 1000)
RANDOMISE (2000 patients)
During post-operative period Hb / Hct levels 
monitored as per normal practice.  
Hb falls below 9.0g/dL / Hct below 27? 
Eligible patients 
Obtain written informed consent pre-surgery
Patient registration (about 3000 patients)
Unique study ID allocated
Patient becomes eligible for main study 
YES
NO Patient does not enter main study
Postal QoL assessment 6-weeks post-randomisation
Fig. 1. Trial schema.
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cardiac surgeon, anaesthetist and cardiologist who are
external to the study and blinded to allocation. Death is
not included as a component of the primary composite
outcome because, if death occurs because of one of the
included components, the component will precede death
itself. Deaths that occur for other reasons are not hypothe-
sised to increase because of RBC transfusion.
2.4.2. Secondary outcomes
The following secondary outcomes are collected in the
three month follow-up period (unless otherwise stated):
– Units of RBCs and other blood components transfused
during a participant’s hospital stay.
– Proportion of patients experiencing an infectious event.
– Proportion of patients experiencing an ischaemic event.
– Health-related quality of life using the EuroQol EQ5D
[26].
– Duration of ICU / high dependency unit post-operative
stay;
– Duration of post-operative hospital stay.
– All-cause mortality.– Cumulative resource use, cost, and cost-effectiveness.
– Signiﬁcant pulmonary morbidity, comprising: (a) initia-
tion of non-invasive ventilation (e.g. continuous posi-
tive airway pressure ventilation); (b) re-intubation/
ventilation; and/or (c) tracheostomy. This outcome
was added after starting recruitment as a proxy for
transfusion related acute lung injury.
In addition, all serious adverse events (SAEs) in the
3 month follow-up period are reported (both expected
events listed in the study protocol and unexpected events).
2.5. Data collection
For all participants who consent, data collection pre-
operatively consists of medical history, demographic data,
Hb level, medication use and type of cardiac surgery (e.g
CABG, valve implantation). The participant is also asked
to complete a generic quality of life questionnaire, the
EuroQol EQ5D questionnaire. The lowest Hb recorded on
each post-operative day is documented.
For randomised participants all transfusions are
recorded, including any transfusion decisions that are
Table 2
Deﬁnition of serious infectious/ischaemic events for primary outcome.
Deﬁnition/method of veriﬁcation
Infectious events
Sepsis during index Deﬁned by the following two conditions, both of which must be satisﬁed for sepsis to be documented:
admission (a) Antibiotic treatment for suspected infection, and
(b) The presence of systemic inﬂammatory response syndrome (SIRS)a within 24 h prior to start of antibiotic
treatment
Wound infection ASEPSIS [38] score >20. Wounds will be assessed at least once during a participant’s hospital stay and details of the ASEPSIS
assessment added to the study CRF. A questionnaire will be posted for self-completion, or will be administered by
telephone, at 3 months to identify wound infections arising after discharge [24]
Ischaemic events
Permanent stroke Clinical report of brain imaging (computed tomography or magnetic resonance imaging), in association with new onset
focal or generalised neurological deﬁcit (deﬁned as deﬁcit in motor, sensory or co-ordination functions)
MI Elevated post-operative peak serum Troponin I or Tb
AKI AKI Network criteria for AKI, stage 1, 2 or 3 (see below) [39]
Stage 1:
Serum creatinine increase P0.3 mg/dl (P26.4 lmol/l), OR
>1.5 and 62-fold serum creatinine increase compared to the pre-operative serum creatinine (baseline) value, OR
Urine output <0.5 ml/kg for 6 h.
Stage 2:
>2 and 63-fold serum creatinine increase compared to the pre-operative serum creatinine (baseline) value, OR
Urine output 0.5 ml/kg for >12 h
Stage 3:
>3-fold serum creatinine increase compared to the pre-operative serum creatinine (baseline) value, OR
Serum creatinine P4.0 mg/dl (P354 lmol/l) with an acute increase of at least 0.5 mg/dl (44 lmol/l), OR
Urine output <0.3 ml/kg per hour for 24 h or anuria for 12 h, OR
Need for renal replacement therapy (RRT) irrespective of AKI stage at time of RRT
Gut infarction Laparotomy or post mortem
a SIRS is central to the diagnosis of infective complications. It will be deﬁned asP2 of the following conditions: temperature >38 C or <36 C; heart rate
>90 beats/minute; respiratory rate >20 breaths/min or PaCO2 <32 mm Hg or <4.3 kPa; white blood cell count >12,000/mm3 or <4000/mm3. Blood test
results and temperature will be classiﬁed using standard reference ranges.
b Criterion levels of troponin I and T for deﬁning a post-operative MI have not been established. MIs will be adjudicated by an independent committee
blinded to allocation.
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sions (i.e. either a transfusion is given when the threshold
is not breached, or a transfusion withheld when the
threshold is breached) the Hb level at the time and reason
for making the decision are documented. During a partici-
pant’s hospital stay, data are collected for the primary out-
come (e.g. temperature, heart rate, respiratory rate, results
of haematology and biochemistry investigations, ASEPSIS
assessments of wounds for infection), secondary outcomes
(e.g. duration of intensive/high dependency care), and
other key resources used (e.g. return to theatre, medica-
tions, units of blood components transfused).
The consultant responsible for a participant may decide
it is in the best interests of a participant to permanently
discontinue treatment according to the allocated group. If
so, then the reason(s) for this decision must be docu-
mented. The participant is not withdrawn from the trial
and the participant is followed up. If a participant with-
draws consent at any time, the participant no longer forms
part of the study but may be included in the analysis co-
hort if willing for data already collected to be used.
Three months after randomisation, a questionnaire is
posted for self-completion or administered by telephone.
It includes the following elements: (a) adverse events
(AEs) occurring after discharge, with further details of
any event suspected to contribute to the primary outcome
or to meet the deﬁnition of a SAE being sought, e.g. fromthe admitting hospital or the participant’s general practi-
tioner (GP); (b) questions to identify surgical wound infec-
tions occurring after discharge (ASEPSIS post-discharge
surveillance questionnaire) [24]; (c) resource use question-
naire; (d) questions determining whether a participant is
aware of his/her random allocation.
Finally, the EuroQol EQ5D [26] is posted to participants
at six weeks and three months post-randomisation. Partic-
ipants who are registered into the study but are not ran-
domised also receive the EuroQol EQ5D three months
after their operation. Descriptive summaries of their EQ5D
scores will be compared to those of randomised patients.
2.6. Sample size
The trial is designed to test a superiority hypothesis.
The following steps were undertaken to calculate the re-
quired sample size:
1. Risks of transfusion in the two groups are critical to the
success of the trial. Data for the distribution of nadir Hb
and Hct from an observational analysis published
shortly before funding was awarded are shown in
Fig. 2 [2]. Based on these data, we assumed that approx-
imately 65% of patients would breach the threshold of
9.0 g/dL, and approximately 20% would breach the
7.5 g/dL threshold.
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protocol, we assumed that 100% of participants ran-
domised to the liberal group and 30% of participants
randomised to the restrictive group (0.20/0.65) would
be transfused.
3. In the observational analysis [2], 63% of patients with a
nadir Hct between 22.5% and 27% and 93% of patients
with a nadir Hct below 22.5 were transfused. Therefore,
in combination with the proportions of patients
expected to breach the liberal and restrictive thresh-
olds, these ﬁgures were used to give conservative esti-
mated transfusion rates of 74% for the liberal group
and 635% for the restrictive group, i.e. assuming some
non-adherence with the transfusion protocol severe
enough to alter transfusion rates in each group (Fig. 3).
4. The observational estimate of the relative risk for any
compared to no transfusion was adjusted to reﬂect
the estimated transfusion rates in the two groups and
combined with the frequency of infections and ischae-
mic events observed in the untransfused group, giving
event rates of the proposed composite outcome of 17%
in the liberal threshold group, and 11% in the restrictive
threshold group, a risk difference of 6%. A sample size of
1468 was required to detect this difference with 90%
power with 5% signiﬁcance (2-sided test).
5. The target sample size was inﬂated to 2000 patients (i.e.
1000 in each arm) to allow for uncertainty about non-
adherence that affects transfusion rates and the esti-
mated proportions of patients experiencing the primary
outcome. We regarded these parameter estimates as
uncertain because: (a) they were estimated from obser-
vational data; (b) they were based on the RBC transfu-
sion rate only in Bristol for over seven years; (c) they
were based on routinely collected data, using deﬁni-
tions for elements of the composite primary outcome0
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Fig. 2. Data for the distribution of nadir haemoglobin/haematocrit from
recent observational analysis [2] both for the entire dataset (n = 8621,
solid line) and for the most recent data (2003; n = 1106, dashed line).
Vertical lines represent the restrictive and liberal protocols compared in
this trial. Notes: The most recent data show a slight shift in the
cumulative frequency plot towards higher Hb, probably because of wider
uptake of off-pump CABG surgery, which causes less blood loss, over the
period represented by the data. Data describing nadir Hb were obtained
speciﬁcally for the analysis and we have not linked the clinical and
haematology databases for more recent years. However, the proportion of
offpump CABG has not continued to increase since 2003.which are not identical to those proposed for the trial;
(d) they were based on any versus no RBC transfusion,
rather than on the number of units of RBCs likely to
be transfused in patients who breach the liberal
threshold.
The primary outcome measure for the economic evalu-
ation is quality adjusted life years (QALYs). The analysis
will include baseline QALYs as a covariate and the correla-
tion between baseline and three month assessments of
QALYs was assumed to be P0.3. With a total sample size
of 2000, the trial will have >95% power to detect a stand-
ardised difference in continuous outcomes between groups
of 0.2% with 1% signiﬁcance (2-sided test). This magnitude
of difference is conventionally considered to be ‘‘small’’
[27].
2.7. Randomisation
Participants are randomised using a third party inter-
net-based system (Sealed Envelope Ltd.; www.sealedenve-
lope.com). Staff in participating centres access the system
using a password and pin number. Patients become eligible
for randomisation if their haemoglobin falls below 9 g/dL
at any point post-operatively. At this time information to
identify a participant uniquely and to conﬁrm eligibility
must be entered before the system assigns a randomisa-
tion number and the treatment allocation, ensuring con-
cealment of allocations. Participants are allocated to the
liberal or restrictive transfusion strategies in a 1:1 ratio,
and cohort minimisation is used to achieve balance across
the two arms of the trial; minimisation factors are centre
and operation type (CABG only; Valve only; CABG and
valve; Other).
2.8. Blinding
Every effort is made to blind participants to their alloca-
tion. The success of participant blinding is checked by ask-
ing participants if they knew what their allocation was at
the time of their discharge from hospital and at three
months. It is not possible to blind clinicians and other
health care staff caring for patients to the random alloca-
tion of participants. Therefore, special care has been taken
to deﬁne outcomes on the basis of objective criteria, or
adjudication, in order to reduce the risk of bias.
2.9. Statistical methods
All analyses of primary and secondary outcomes will be
on an intention-to-treat basis. Full details of the statistical
methods used are given elsewhere [28]. In brief, the pri-
mary outcome will be analysed using logistic regression
with the following pre-speciﬁed subgroup analyses being
carried out: (a) operation type, (b) age, (c) pre-operative
diagnosis of diabetes or not, (d) pre-operative diagnosis
of lung disease, (e) pre-operative renal impairment, (f)
sex and (g) ventricular function. Secondary outcomes will
be analysed using logistic regression, Cox regression or lin-
ear regression, as appropriate. An interim analysis will be
carried out after 50% of patients have been recruited and
TRANSFUSION THRESHOLD
Nadir Hb 
<7.5g/dL
Nadir Hb Total
TRANSFUSED 96% 62% 74%
NOT 
TRANSFUSED
4% 38% 26%
TRANSFUSION THRESHOLD
Nadir Hb 
<7.5g/dL
Nadir Hb Total
TRANSFUSED 96% <5% <35%
NOT 
TRANSFUSED
4% >=95% >=65%
All Cardiac Surgery Patients (100%)
Eligible patients who consent (28%)
Baseline data including EQ5D (28%)
Operation carried out (28%)
Nadir haemoglobin (Hb) <9.0g/dL (18%),
randomised to:
Transfusion threshold: Hb <9.0g/dL Transfusion threshold: Hb <7.5g/dL
Other exclusions / 
Not approached /  65.3%
Declined to take part 
Emergency operations 3.8%
Early post-operative 0.3% 
deaths (very few)
Nadir Hb>=9.0g/dL 9.6%
Fig. 3. CONSORT diagram summarising TITRe 2 trial design. Notes: Percentages are based on data from the cardiac surgery registry in Bristol for the period
Jan to Sep 2007. An unknown percentage of patients are excluded by the exclusion criteria because the registry does not contain sufﬁcient detail to apply
the deﬁnitions proposed for the trial. However, patients meeting one or more of these criteria are extremely rare and we expect all of the exclusion criteria
to account for a maximum of 5% of cardiac surgery patients.
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will be carried out: (a) estimating the dose-response rela-
tionship between the number of RBC units transfused
and the risk of mortality and morbidity, with the ﬁndings
of these analyses compared for consistency with previous
ﬁndings [2]; (b) investigating whether RBC ‘age’ is associ-
ated with the risk of both primary and secondary out-
comes; and (c) investigating of the relationship between
the percentage decline in Hb (from preoperative value)
and the risk of primary and secondary outcomes.
2.10. Economic evaluation
The economic evaluation is being undertaken from an
NHS and personal social services perspective. A cost-utility
analysis is being conducted since the primary outcome
measure for the economic evaluation is QALYs. Established
guidelines from National Institute for Health and Care
Excellence (NICE) (UK) will be followed [29].
Resource use data collection has been integrated into
the study CRFs. During the index hospital admission,
detailed data are being collected on blood products trans-
fused, inpatient days by ward type, surgery and re-opera-
tions, medications and any complications and their
treatment. At three months post-randomisation, a bespoke
resource use questionnaire is used to obtain estimates of
healthcare resources used since hospital discharge, for
example readmissions to hospital and further contact with
health professionals in primary or secondary care such as
outpatient appointments and GP visits. Unit costs from
nationally published sources such as NHS Reference Costs
and Unit Costs of Health and Social Care 2012 [30,31] will
then be applied to these resources, and the total costs per
patient calculated.QALYs will be estimated using the EuroQol EQ5D, which
is administered to patients pre-operatively, and at 6 weeks
and 3 months post-randomisation [26]. Respondents will
be assigned valuations derived from published UK popula-
tion tariffs [32] and the QALYs gained per patient
calculated.
Any missing cost and outcome data will be dealt with
using multiple imputation methods [33] The average costs
and QALYs gained in each trial arm will be calculated, and
from this the incremental cost-effectiveness ratio will be
derived, producing an incremental cost per QALY gained
of the restrictive threshold compared to the liberal thresh-
old. The restrictive threshold will be considered cost-effec-
tive if the incremental cost-effectiveness ratio falls below
£20,000, the level below which NICE generally recom-
mends interventions to the NHS [34].
Deterministic and probabilistic sensitivity analysis will
be used to assess the impact on results of variation around
key parameters such as costs for treatments of complica-
tions. Results will be expressed in terms of a cost-effective-
ness acceptability curve, which indicates the likelihood
that the restrictive threshold is cost-effective for different
levels of willingness to pay for health gain.
2.11. Safety reporting
Safety data are collected for all participants for the
duration of their follow-up in the trial. AEs and SAEs are
deﬁned as required by International Conference for Har-
monisation of Good Clinical Practice (ICH GCP). Many
AEs, including death, are listed in the protocol as ‘expected
occurrences not subject to expedited reporting’ (see Table 3
for a list of such events). Other AEs that meet the deﬁnition
of a SAE are deﬁned as unexpected SAEs. Furthermore, an
Table 3
Expected adverse events listed in the study protocol.
Any element of the infectious/ischaemic events as part of the composite primary outcome, including:
 Sepsis
 Wound infection
 Permanent stroke
 MI
 AKI
 Gut infarction
Transient ischaemic attack
Other gastro-intestinal complications, including:
 Pancreatitis
 Obstruction or perforation
Post-operative haemorrhage
Cardiac tamponade
Pulmonary complications, including:
 Acute respiratory distress syndrome
 Re-intubation and ventilation
 Tracheostomy
 Initiation of mask continuous positive airway pressure ventilation after weaning from ventilation
 Pneumothorax requiring chest drainage
 Pleural effusion requiring drainage
Arrhythmias, including:
 Supraventricular tachycardia or atrial ﬁbrillation requiring treatment
 Ventricular ﬁbrillation or tachycardia requiring intervention
 Pacing
Re-operation for any reason, including:
 Bleeding
 Cardiac arrest
 Mediastinitis
Thromboembolic complications, including:
 Deep vein thrombosis
 Pulmonary embolus
Low cardiac output, requiring management with a Swan-Ganz catheter, an intra-aortic balloon pump, or left ventricular assist device
Wound dehiscence requiring rewiring or treatment for reason other than infection
Death
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that is judged by the local Principal Investigator to be pos-
sibly, probably or deﬁnitely related to allocation to one or
other arm of the trial.
SAEs are recorded and reported in accordance with the
ICH GCP guidelines and the Sponsor’s Research Related Ad-
verse Event Reporting Policy. Data on all AEs and SAEs are
collated and reported regularly to the Data Monitoring and
Ethics Committee (DMEC), distinguishing SAEs that occur
in the same participants.
2.12. Funding and regulatory bodies
The trial is funded by the National Institute for Health
Research Health Technology Assessment Programme
(Project Number 06/402/94) and sponsored by University
Hospitals Bristol Foundation NHS Trust. The study protocol
has been reviewed and approved by the ‘Oxfordshire
Research Ethics Committee (REC) C’ (REC ref: 08/H0606/
125). The study is being conducted in accordance with:
relevant aspects of the Medicine for Human Use (Clinical
Trial) Regulations 2004; ICH GCP guidelines; Research
Governance Framework for Health and Social Care; the
UK Data Protection Act 1998.
3. Discussion
The TITRe2 trial presents a unique opportunity to an-
swer a fundamental question about a clinical interventionthat is administered to 90% of cardiac surgery patients in
some centres and over 50% of all patients in the UK and
elsewhere. When the trial was conceived, there was no
previous high quality RCT of alternative RBC transfusion
thresholds in patients having cardiac surgery to date (other
than the pilot study for this trial, which was greatly under-
powered). It is important to investigate this question in pa-
tients having cardiac surgery because, compared to other
patient populations, these patients are considered to be
at greater risk of myocardial ischaemia due to coronary ar-
tery disease, and systemic tissue hypoxia in the presence of
severe anaemia due to impaired cardiac output. In addi-
tion, cardiac surgery is a specialty which uses a large
amount of blood. Increasing recognition of the risks of
RBC transfusion [35], coupled with the increasing costs of
this potentially diminishing resource, had led to calls for
good quality RCTs to determine the relative risks and ben-
eﬁts of anaemia and RBC transfusion in this population
[36]. However, there have been several obstacles to over-
come in setting up and conducting the study.
The choice of Hb thresholds for transfusion proved
problematic. Thresholds for transfusion are controversial
and different people argue for different thresholds. Our
choice of thresholds takes into account that: (a) the thresh-
olds span a ‘densely populated’ part of the distribution of
nadir Hb (see Fig. 2); (b) in cardiac intensive care, either
transfusing at Hb >9.0 g/dL or not transfusing until the
Hb drops below 7.0 g/dL was considered unacceptable by
most clinicians; (c) a reasonable difference between the
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with a feasible sample size. Therefore, the thresholds rep-
resent a compromise which spans the range of contempo-
rary international practice. Among clinicians in interested
centres, despite some unease at transfusing outside their
existing protocols in some instances, there is a willingness
to accept the proposed thresholds because of the perceived
urgency of addressing the research question.
Assumptions for the sample size calculation highlighted
our concern about adherence. The DMEC was, in particular,
anxious that transfusions in the liberal group might be
withheld or delayed causing convergence of the transfu-
sion rates of the two groups, particularly as interested sites
tended to err on the lower side of transfusion thresholds in
cardiac surgery. Therefore, complex methods of monitor-
ing and categorising non-adherence have been imple-
mented. Two main types of non-adherence have been
identiﬁed: (a) giving transfusions outside of protocol and
(b) withholding transfusions, and both types have been
further categorised into mild, moderate or severe depend-
ing on the likely impact on transfusion risks (any transfu-
sion versus no transfusion). We believe that TITRe2 is
unique in attempting to document the latter.
Severe instances are those that will affect the overall
transfusion rate in each group. Mild and moderate can only
affect the total numbers of RBC units and/or timing of
transfusions. Currently around 38% of patients have had
one or more instances of non-adherence with the transfu-
sion protocol, with the instance deemed ‘‘severe’’ for
approximately 8% of patients. The former ﬁgure is similar
to the overall non-adherence rate of 38% from a recent pi-
lot study investigating adherence to transfusion strategies
in cardiac surgery; however, in this pilot study the inter-
vention period included the intra-operative period [37].
The latter ﬁgure of approximately 8% ‘‘severe’’ non-adher-
ence is comparable to the frequency of severe protocol
breaches reported in the recent FOCUS trial [17]. Whilst
rates of non-adherence in TITRe2 are somewhat high, these
rates have been deemed acceptable by the DMEC, reﬂect-
ing the pragmatic nature of the study. Furthermore, the
severe non-adherence rate, which impacts on the compar-
ison between groups of the proportion having any transfu-
sion, is consistent with the assumptions underpinning the
sample size calculation.
At the start of the trial, recruitment was much slower
than anticipated due to delays in ﬁnalising and obtaining
signed site agreements and NHS approvals. Once sites
started recruiting, the initial projection of 19 consented pa-
tients per site per month was found to be over-optimistic
(although achieved by the Chief Investigator’s site), with
sites achieving eight consented patients per month on
average. Slower recruitment is thought to be due to a num-
ber of reasons including: (a) staff availability for the study
in local site teams, with the impact of research nurse an-
nual leave and sick leave extending to one week either side
of actual absence; (b) emerging competing studies at some
sites not registered at the TITRe2 set-up stage; (c) not all
surgeons at sites being willing to take part. The study
management team examines recruitment rates and
characteristics of sites frequently and holds discussionswith sites about rate-limiting steps to recruitment. News-
letters and regular investigator meetings (with research
nurses attending) are also used to update sites and to rein-
force important messages. Finally, the randomisation pro-
portion has been lower than the projected 65%, meaning
that more patients need to be consented into the study
than anticipated. At the start of the study the randomisa-
tion proportion was less than 50%; however examination
of the characteristics of randomised and non-randomised
patients led to recommendations to sites to target patients
having off-pump cardiac surgery, as well as urgent (inpa-
tient) cases, where possible. This has led to an increase in
the randomisation proportion to around 58%, although this
is still somewhat lower than originally predicted. Some eli-
gible patients have also been missed, contributing to the
reduced randomisation proportion. All of these issues led
to a successful application to the funder to extend the
duration of the trial and open additional centres. During
the course of the extension recruitment has been consis-
tent with the revised projections.
Data collection is complex and more time-consuming
than anticipated. In order to ensure that transfusions are
given according to the protocol for the allocated group,
Hb levels are required for every post-operative day, as well
as at each ‘‘breach’’ of the allocated threshold and at each
transfusion. The timing of each breach and transfusion is
also required, along with the reasons why a transfusion
is not given when indicated, or given outside of protocol.
Although most patients are discharged within 10 days of
their operation, around 25% of the study population stay
longer (so far the longest stay has been 85 days) and data
collection for these patients is demanding. In addition,
the need to use objective criteria to deﬁne primary out-
come events (e.g. sepsis) means data collection is multi-
faceted with a number of different observations required.
In response to feedback from sites the study CRFs were
substantially revised after approximately nine months of
recruitment, with consequent improvement in the efﬁ-
ciency of data collection. In addition, the payment per pa-
tient that sites receive has been increased to reﬂect the
higher than predicted number of hours of research nurse
time required for each patient.
The primary outcome event rate has been substantially
higher than anticipated in the sample size calculation
(approximately 34%). This appears to be due to: (a) on aver-
age, a higher-risk population being randomised into the
study than in the previous observational study, and (b)
the use of objective criteria to deﬁne sepsis and AKI, com-
pared to clinical recording of these events. Consequently,
a sensitivity analysis focusing only on more serious events
has been included in the statistical analysis plan [28].4. Conclusion
In summary, despite the complex nature of the study
and challenging data collection requirements, the trial
has proceeded successfully. Lessons learnt from TITRe2
should help to design and conduct future transfusion based
studies.
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